HIV Population Dynamics

Chapter
First Online:

Abstract

HIV-1 infection usually starts with the transmission of a single virion that expands and diversifies over time resulting in a chronic infection that eventually leads to the loss of immune function. Treatment with combinations of antiretroviral compounds nearly or completely blocks the infection of new cells by inhibiting the function of viral enzymes, such as reverse transcriptase, allowing the immune system to rebound. Studying HIV-1 population dynamics, such as ongoing replication, diversity, and evolution, provides insight into viral transmission, pathogenesis, persistence during antiretroviral therapy (ART), and strategies for eradication. In this chapter, we will introduce and discuss the dynamics and the genetics of HIV-1 populations in both treated and untreated individuals.

Keywords

Infected Cell Simian Immunodeficiency Virus Virologic Failure Virus Population Human Leukocyte Antigen Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T (2011) Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117:2791–2799PubMedCrossRefGoogle Scholar
  2. Balagam R, Singh V, Sagi AR, Dixit NM (2011) Taking multiple infections of cells and recombination into account leads to small within-host effective-population-size estimates of HIV-1. PLoS One 6:e14531PubMedCrossRefGoogle Scholar
  3. Batorsky R, Kearney MF, Palmer SE, Maldarelli F, Rouzine IM, Coffin JM (2011) Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection. Proc Natl Acad Sci USA 108:5661–5666PubMedCrossRefGoogle Scholar
  4. Boltz VF, Zheng Y, Lockman S, Hong F, Halvas EK, McIntyre J, Currier JS, Chibowa MC, Kanyama C, Nair A, Owino-Ong’or W, Hughes M, Coffin JM, Mellors JW (2011) Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA 108:9202–9207PubMedCrossRefGoogle Scholar
  5. Boltz VF, Ambrose Z, Kearney MF, Shao W, KewalRamani VN, Maldarelli F, Mellors JW, Coffin JM (2012a) Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with RT-SHIV. J Virol 86:12525–12530PubMedCrossRefGoogle Scholar
  6. Boltz VF, Bao Y, Lockman S, Halvas EK, McIntyre JA, Schooley R, Hughes MD, Coffin JM, Mellors JW, Team OA (2012b) The risk of virologic failure associated with low frequency NVP-resistant variants depends on prior exposure to single dose Nevirapine: OCTANE/ACTG 5208 Trial 1 and Trial 2. Oral presentation at the 19th Conference on Retroviruses and Opportunistic InfectionsGoogle Scholar
  7. Brown AJ (1997) Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci USA 94:1862–1865PubMedCrossRefGoogle Scholar
  8. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA, Boucher G, Haddad EK, Sekaly RP, Harman AN, Anderson JL, Jones KL, Mak J, Cunningham AL, Jaworowski A, Lewin SR (2010) Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci USA 107:16934–16939PubMedCrossRefGoogle Scholar
  9. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell J, Bixby D, Savona MR, Collins KL (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16:446–451PubMedCrossRefGoogle Scholar
  10. Chakrabarti LA (2004) The paradox of simian immunodeficiency virus infection in sooty mangabeys: active viral replication without disease progression. Front Biosci J Virt Libr 9:521–539CrossRefGoogle Scholar
  11. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF (1997a) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183–188PubMedCrossRefGoogle Scholar
  12. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS (1997b) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94:13193–13197PubMedCrossRefGoogle Scholar
  13. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483–489PubMedCrossRefGoogle Scholar
  14. Demma LJ, Jr Logsdon JM, Vanderford TH, Feinberg MB, Staprans SI (2005) SIVsm quasispecies adaptation to a new simian host. PLoS Pathog 1:e3PubMedCrossRefGoogle Scholar
  15. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O’Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 106:9403–9408PubMedCrossRefGoogle Scholar
  16. Fauci AS, Desrosiers RC (1997a) Pathogenesis of HIV and SIV. In: Coffin JM, Hughes SH, Varmus HE (eds) Retroviruses. Cold Spring Harbor, New YorkGoogle Scholar
  17. Fauci AS, Desrosiers RC (1997b) Pathogenesis of HIV and SIV. In: Coffin JM, Hughes SH, Varmus HE (eds) Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p. 587–635Google Scholar
  18. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295–1300PubMedCrossRefGoogle Scholar
  19. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ (2000) Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74:6262–6268PubMedCrossRefGoogle Scholar
  20. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7(8)Google Scholar
  21. Hirsch VM (2004) What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS Rev 6:40–53PubMedGoogle Scholar
  22. Josefsson L, King MS, Makitalo B, Brannstrom J, Shao W, Maldarelli F, Kearney MF, Hu WS, Chen J, Gaines H, Mellors JW, Albert J, Coffin JM, Palmer SE (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci USA 108:11199–11204PubMedCrossRefGoogle Scholar
  23. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, Meese E, Wain-Hobson S, Meyerhans A (2002) Recombination: multiply infected spleen cells in HIV patients. Nature 418:144PubMedCrossRefGoogle Scholar
  24. Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S (2009) Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 83:2715–2727PubMedCrossRefGoogle Scholar
  25. Kearney M, Spindler J, Shao W, Stephens R, O’Shea A, Rehm C, Poethke C, Mellors JW, Coffin JM, Maldarelli F (2010) Rebound HIV-1 viremia after cessation of long-term suppressive antiretroviral therapy (ART) has low genetic diversity and little divergence from pre-therapy virus populations. Oral presentation at the international HIV & hepatitis virus drug resistance workshop & curative strategiesPubMedCrossRefGoogle Scholar
  26. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523–526PubMedCrossRefGoogle Scholar
  27. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105:7552–7557PubMedCrossRefGoogle Scholar
  28. Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J, Prindiville T, Sankaran-Walters S, Syvanen M, Wong JK, George MD, Dandekar S (2011) The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol 85:4772–4782PubMedCrossRefGoogle Scholar
  29. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B (2012) Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 17:355–364PubMedCrossRefGoogle Scholar
  30. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3:e46PubMedCrossRefGoogle Scholar
  31. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087–5094PubMedGoogle Scholar
  32. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50:912–919PubMedCrossRefGoogle Scholar
  33. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167–1170PubMedCrossRefGoogle Scholar
  34. Mens H, Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J, Obel N, Maldarelli F, Mellors JW, Benfield T, Coffin JM (2010) HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 84:12971–12981PubMedCrossRefGoogle Scholar
  35. Neher RA, Leitner T (2010) Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput Biol 6:e1000660PubMedCrossRefGoogle Scholar
  36. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105:3879–3884PubMedCrossRefGoogle Scholar
  37. Rouzine IM, Coffin JM (1999) Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci USA 96:10758–10763PubMedCrossRefGoogle Scholar
  38. Rouzine IM, Coffin JM (2005) Evolution of HIV under selection and weak recombination. Genetics 170:7–18PubMedCrossRefGoogle Scholar
  39. Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D (2002) Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 76:9481–9492PubMedCrossRefGoogle Scholar
  40. Salgado M, Rabi SA, O’Connell KA, Buckheit RW 3rd, Bailey JR, Chaudhry AA, Breaud AR, Marzinke MA, Clarke W, Margolick JB, Siliciano RF, Blankson JN (2011) Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology 8:97PubMedCrossRefGoogle Scholar
  41. Schnell G, Price RW, Swanstrom R, Spudich S (2010) Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol 84:2395–2407PubMedCrossRefGoogle Scholar
  42. Shankarappa R, Gupta P, Learn GH Jr, Rodrigo AG, Rinaldo CR Jr, Gorry MC, Mullins JI, Nara PL, Ehrlich GD (1998) Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology 241:251–259PubMedCrossRefGoogle Scholar
  43. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73:10489–10502PubMedGoogle Scholar
  44. Sharkey ME, Stevenson M (2001) Two long terminal repeat circles and persistent HIV-1 replication. Curr Opin Infect Dis 14:5–11PubMedCrossRefGoogle Scholar
  45. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Brown AJ (1990) Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 64:864–872PubMedGoogle Scholar
  46. Svarovskaia ES, Cheslock SR, Zhang WH, Hu WS, Pathak VK (2003) Retroviral mutation rates and reverse transcriptase fidelity. Front Biosci J Virt Libr 8:d117–d134CrossRefGoogle Scholar
  47. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, Pawluk DM, Mohan KM, Lewis PF, Mullins JI, Frenkel LM (2005) Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 79:9625–9634PubMedCrossRefGoogle Scholar
  48. Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, Pasternak A, Florence E, Vanham G (2012) Immune and viral correlates of “secondary viral control” after treatment interruption in chronically HIV-1 infected patients. PLoS One 7:e37792PubMedCrossRefGoogle Scholar
  49. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, Loul S, Butel C, Liegeois F, Bienvenue Y, Ngolle EM, Sharp PM, Shaw GM, Delaporte E, Hahn BH, Peeters M (2006) Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 444:164PubMedCrossRefGoogle Scholar
  50. Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, Ho YS, Saksena NK, Hoy J, Crowe SM, Cameron PU, Lewin SR (2010) Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 202:1738–1748PubMedCrossRefGoogle Scholar
  51. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291–1295PubMedCrossRefGoogle Scholar
  52. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Gunthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK (2010) Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 202:1553–1561PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.National Cancer InstituteFrederickUSA
  2. 2.Tufts UniversityBostonUSA

Personalised recommendations